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Abstract
Background: The objective of this study was to analyze prescription decisions for family practice (FP) patients with
Diabetes mellitus type 2 (DM2) using the case of the incretin mimetics Dipeptidyl peptidase-4 (DDP-4) inhibitors
and Glucagon-like peptide-1 (GLP-1) agonists dependent on patients’ health insurance status (statutory or private)
in Germany. This study is important since the scientific debate is still open with regard to DPP-4-inhibitors
and GLP-1-agonists, where some critics are raising questions on potential long-term risks for patients.
Methods: Data for this analysis were sourced from the German health services research register CONTENT
(CONTinuous morbidity registration Epidemiologic NeTwork), in which FP health services information, generated by
family practitioners, is continuously collated, e.g. patients’ health insurance status, morbidity and pharmacotherapy.
Patients with Diabetes mellitus type 1 (DM1) were excluded from the study.
Results: From the family practices collaborating in the CONTENT research network, there were 7298 patients treated
with pharmacotherapeutic agents for DM2 between 01.09.2009 and 31.08.2014. 586 (8.03 %) of these patients had
private insurance. Prescriptions for the incretin mimetics were 40.6 % higher (9.7 vs. 6.9 %; p < 0.0001) for patients with
private insurance compared to patients with statutory health insurance. This finding was confirmed with multivariable
analyses.
Conclusions: There was a statistically significant difference found in prescription patterns according to the patient’s
health insurance status for the incretin mimetics in this sample population of German patients with DM2. Obviously,
these differences result from the eligibility for reimbursement according to patients’ health insurance status. Whether
incretin mimetics pose specific long term risks for particular patients is yet to be determined.
Background
In the German health care system, there are two coexist-
ing health insurance types (statutory or private) for indi-
viduals. These types differ in terms of contribution,
access to health care services and reimbursement. The
main differences are shown in Table 1.
The last row of Table 1 highlights that there are some
restrictions for statutorily insured patients. In particular,
differences in reimbursement for certain drugs can
result in different prescribing decisions of family practi-
tioners (FPs).
The objective of this study was to analyze this issue in
a German family practice setting by examining FP
prescription practices for patients with Diabetes melli-
tus type 2 (DM2) using the case of the incretin mi-
metics Dipeptidyl peptidase-4 (DDP-4) inhibitors and
Glucagon-like peptide-1 (GLP-1) agonists.
The use of oral antihyperglycaemic agents for treating
patients with DM2 is recommended when lifestyle inter-
ventions alone, including eating healthily, exercising regu-
larly and losing weight, prove inadequate in maintaining
blood glucose at target levels. In such cases, the oral bi-
guanide, Metformin, is the first-line agent recommended
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in clinical guidelines [1]. Other agents should be consid-
ered whenever the use of Metformin is not possible or not
sufficient.
These stepped recommendations are especially true
for the “German National Guideline” for DM2. The
current version of the guideline is very considerable and
covers more than 250 pages [2]. The guideline is well
structured and copes with the complexity associated
with DM2. Both general recommendations and special-
ities important in DM2 disease management are consid-
ered adequately. Importantly, recommendations are
given under consideration of existing national and inter-
national evidence. DPP-4 inhibitors and GLP-1 agonists
are explicitly addressed in this guideline. Within the
current version, both agents are classified as “antidia-
betics without ascertained advantageous influence on
clinical endpoints”. However, it is stated that there is no
intrinsic risk of hypoglycaemia, neither for DPP-4 inhibi-
tors nor for GLP-1 agonists. The DPP-4 inhibitor active
agents “Sitagliptin” and “Vildagliptin” are permitted as
monotherapy according to the current German guideline
only if an intolerance to Metformin is observed. GLP-1
agonists should only be taken into account in combination
with other oral antihyperglycaemic agents (preferably
Metformin) for patients with severe weight problems,
disposition to hypoglycaemia and/or cardiovascular prob-
lems, where Sulfonylurea are contraindicated.
Overall, there is currently a lack of consensus regard-
ing the management of DM2 patients that fail to re-
spond to initial monotherapy with metformin. New
antihyperglycaemic agents such as DDP-4 inhibitors and
GLP-1 agonists have entered the market and are being
used either as a monotherapy or in addition to metfor-
min [1]. As a result, when managing patients with DM2,
the treating physician – commonly a FP – may now
prescribe from an extensive range of pharmacotherapeu-
tic agents. This includes the new classes of diabetic
drugs such as DPP-4-inhibitors and GLP-1-agonists,
which remain under patent protection and are therefore
quite expensive. According to the German Diabetes As-
sociation (DDG), the primary advantage of DPP-4 inhibi-
tors in comparison to the older sulfonylureas is the
decreased risk of hypoglycaemia. An additional effect is
a reduction in appetite and thus the reduced likelihood
of weight gain [3]. These effects have been confirmed in
various international studies on DPP-4-inhibitors and
GLP-1-agonists [4]. Nevertheless, to date, there is little
international evidence on the long-term risks for pa-
tients with these new classes of diabetic drugs.
Aside from taking into account therapeutic consider-
ations and potential long-term risks, other factors such
as eligibility for reimbursement and funding volumes
steer German FPs when making prescribing decisions.
When writing prescriptions, German FPs are expected
to comply with requirements for cost-effectiveness (and
in some cases prescription targets) set out in the guide-
lines on funding volumes from the statutory health insur-
ance organisations [5]. However, cost-control restrictions
on prescribing in this form do not exist for patients cov-
ered by private health insurance. Although there are
legally required rebates on prescription drugs connected
to patients with private health insurance, these have no
specific financial implications for the prescribing FP.
Therefore, the object of this study was to examine FP
prescribing patterns for the incretin mimetics DPP-4-
inhibitors and GLP-1-agonists.
Of particular interest, while taking into account
context-relevant covariates (age, sex, mortality, family
practice), was the factor of patient health insurance status
i.e. private or statutory and possible different prescription
Table 1 Characteristics of statutory and private health insurance in Germany
Characteristic Statutory Health Insurance Private Insurance
Principle of insurance Principle of solidarity.
Health care has to be economical and medically necessary.
More than 90 % of German inhabitants have statutory
health insurance.
Principle of equivalence.
Policy of equivalence of service and reward.
Less than 10 % of German inhabitants are privately insured.
Self-employed persons and persons with an annual salary
above 54,900€ have the option of private health insurance.
Insurance contribution Health insurance contribution currently 14.6 % of the
individual’s gross income. Additional contributions are
possible.
Contribution dependent on age, sex, individual health risk and
chosen services.
Access to health care
system
Medical care of authorised physicians, authorized dentists
and if possible inpatient treatment in the nearest hospital.
Free selection of physicians, dentists and hospitals.
Settlement of medical
services
Billing of the medical services directly to the health
insurance company.
Billing of the medical services directly to the patients, who







Limitation of budgets regarding patented medication.
Prescription of generic drugs, if possible.
No restrictions.
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patterns of FPs according to the respective health in-
surance status.
Methods
Data for this analysis were sourced from a German
health services research Register, in which primary care
health care information, generated by family practices, is
continuously collated e.g. patients’ health insurance sta-
tus (statutory or private), morbidity, disease progression
and health care outcomes. This Register is overseen by
the Research Network CONTENT (CONTinuous mor-
bidity registration Epidemiologic NeTwork), which was
established through a grant from the German Federal
Ministry of Education and Research (BMBF) [6, 7]. Par-
ticipation is voluntary for FPs. There are two software
companies (namely “Quincy” and “S3”) supporting the
CONTENT documentation that is based on both the
ICPC (International Classification for Primary Care) and
the ICD-10. Moreover, the software allows an automa-
tized and secure data export to the central CONTENT
database. For each patient, there is a unique pseudonym.
Due to data protection regulations, the transmitted data
do not contain patient identifying elements (e. g. patient
names). For this study, patient data from 35 FPs were
available, where contributions to the database for the
whole observation period occured.
Uniquely for Germany, is that not only the records on
prescriptions for statutorily health insured patients are
available in the CONTENT register, but also those for
privately insured patients. Furthermore, it is possible to
differentiate between privately insured and statutory in-
sured patients based on individual patient identifier
codes. Prescription data is automatically collected in
electronic patient records when the prescription is
printed. Moreover, due to the central pharmaceutical
numbers (“Pharmazentralnummer”, PZN), it is abso-
lutely clear which medications and active pharmaceutical
ingredients have been prescribed.
Data from 7298 patients from a 5-year cohort
(01.04.2009 to 31.08.2014) that was generated by family
practices collaborating in the CONTENT research net-
work served as the basis for this analysis. These patients
were treated with pharmacotherapeutic agents for DM2.
Patients with Diabetes mellitus type 1 (DM1) were ex-
cluded from this analysis. Total morbidity was calculated
using the Charlson Index [8], in which clinical condi-
tions based on ICD-10 diagnoses were scored and scores
were summed to provide a total morbidity score.
A written informed consent from patients was not ob-
tained. In Germany, anonymized patient data can be
used without written informed consent, if the data are
used for strictly scientific purposes.
In order to determine whether patient health insur-
ance status i.e. private or statutory was a statistically
significant influencing factor, univariate analyses of dif-
ferences between privately insured and statutory insured
patients were made using Fisher’s exact test [9]. Multi-
variable analyses [10] were performed using binary logis-
tical regression under adjustment for age, sex and total
morbidity of patients. In addition, a two-level (doctor,
patient) analysis was conducted. Statistical software used
for these analyses were R (Version 3.1, 64 bit) [11] und
SAS (Version 9.4, 64 bit) [12]. Ethical approval for the
CONTENT project was given by the University Hospital
Heidelberg Ethics Committee (No. 442-2005).
Results
From the family practices collaborating in the CON-
TENT research network, there were 7298 patients
treated with pharmacotherapeutic agents for DM2 be-
tween 01.09.2009 and 31.08.2014. 594 (8.02 %) of these
patients had private insurance. Although average age
was very similar across both groups, the percentage of
females in the group with statutory health insurance was
much higher. In addition, the total morbidity score, ac-
cording to the Charlson Index, was higher in the statu-
tory health insurance group reflecting a higher health
care burden (Table 1).
The average number of antidiabetic prescriptions per
patient was 12.1 ± 15.7 for statutorily and 11.9 ± 14.6 for
privately insured patients (p: n.s.) within the observation
period. Prescriptions for the incretin mimetics were
40.6 % higher (9.7 vs. 6.9 %; p < 0.0001) for patients with
private insurance compared to patients with statutory
health insurance. Equally, when DPP-4-inhibitors and
GLP-1-agonists were analyzed separately, there remained
a statistically significant difference. A particular non
incretin mimetic antidiabetic therapy was totally replaced
by an incretin mimetic therapy for 34.2 % of statutorily in-
sured patients and for 54.7 % of privately insured patients.
For 65.8 and 45.3 % of patients, respectively, an incretin
mimetic therapy was added. The observed difference was
statistically significant (p < 0.0001).
The univariate correlation between type of health in-
surance and prescription for incretin mimetics (OR =
1.44; 95 %-CI:[1.32, 1.57]) was confirmed with a 2-level
(patient, practice) multivariable analysis (Table 2) using
context relevant covariates (age, sex, total morbidity)
(OR = 1.39; 95 %-CI:[1.24, 1.55]; p < 0.0001).
Under consideration of the mentioned covariables, the
“chance” for privately insured patients with DM2 to be
prescribed incretin mimetics was significantly and rele-
vantly higher in comparison to patients with statutory
health insurance in this sample (Tables 2 and 3).
Discussion
Different health insurance types in Germany are associ-
ated with particularly different health care service
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restrictions for the patients. This is especially true in
terms of pharmacotherapy. In this study, we observed
statistically significant differences in prescribing of the
incretin mimetics DPP-4-inhibitors and GLP-1-agonists
in the sample population for patients with DM2 in fam-
ily practice. This analysis cannot prove a causal relation-
ship between differences in eligibility for reimbursement
according to private or statutory health insurance and
prescription patterns for these new classes of diabetic
drugs. However, it is certainly strongly suggestive that
this is the case.
Other data sources show that since these new classes
of diabetic drugs have entered the German market there
is a noteworthy associated flow of finances, at least in the
private insurance sector. According to results published in
the German major 2012 report on pharmacotherapeutic
agents for privately insured patients, a steady increase in
prescriptions for incretin mimetics to the sum of 45.6 M €
(+108.7 %) was reported for the previous 5-year time-
frame. This included DPP-4-inhibitors in combination
with metformin, GLP-1-agonists and also insulin ana-
logues, which reflects as well the aging population [13].
According to the German federal health insurance law,
FPs are required to prescribe statutory insured patients
mimetics when possible and to prescribe new agents in a
reserved manner [14]. Additionally, pharmacies are com-
mitted to dispensing drugs from discount contract drug
suppliers from the patient’s health insurance company
[15]. FPs overriding their prescribing funding volume
are threatened by a reclaim of drug costs from the insur-
ance companies.
In the context of special health insurance company
contracts, FPs have to attend quality circles offered inde-
pendently of pharmaceutical company sponsoring. Dur-
ing these quality circles, current studies and guidelines
are presented and cost-saving potentials are considered.
Feedback reports of the prescriptions of individual FPs
in comparison to all the FPs of one region are generated.
Currently, Germany is facing a tremendous increase in
the prescriptions of incretin based antidiabetics. This is
due to rigorous marketing of the manufacturers address-
ing primarily FPs, internists and diabetologists. Incretin
based drugs are now contributing a major share of total
costs from oral antidiabetic drugs [16]. In our sample,
we could observe a rise for the prescription rate for both
statutorily and privately insured patients over time.
However, the prescription rate for incretin mimetic was
about 40 % higher for privately insured patients in every
observation year.
In the international literature, the debate is still open
with regard to DPP-4-inhibitors and GLP-1-agonists,
where some critics are raising questions on potential
long-term risks for patients. The 2013 critical analysis by
Butler et al. [4] from the University of California made a
Table 2 Prescription patterns for incretin-mimetics with analyzed covariables
Patients with statutory
health insurance
n = 6712 (92.0 %)
Patients with private
health insurance




Average age in years (± SD) 69.9 ± 12.1 69.2 ± 12.1 n. s.
Sex (% female) 53.8 31.1 p < 0.0001
Morbidity (± SD) 1.92 ± 1.78 1.44 ± 1.67 p = 0.0008
Percentage of prescriptions for DPP-4 inhibitors (%) 6.3 8.4 p < 0.0001
Percentage of prescriptions for GLP-1 agonists (%) 0.6 1.3 p < 0.0001
Percentage of prescriptions for incretin-mimetics (%) (DPP-4-inhibitors or
GLP-1-agonists)
6.9 9.7 p < 0.0001
Percentage of patients with at least one incretin-mimetic prescription in
the observation period (%)
15.3 21.0 p < 0.0001
For these patients, in the observation period, there were also prescriptions for
• Insulin, incl. premixed and analogues (%) 24.8 15.4 p = 0.0245
• Metformin as monotherapy (%) 69.9 61.0 p = 0.0497
• Sulfonylurea as monotherapy (%) 30.4 14.6 p = 0.0002
Table 3 Result of multivariable analysis
Covariable Odds Ratio [95 %-CI] Statistical Significance (p-Value)
Age in Years 0.983 [0.981, 0.985] p < 0.0001
Sex (0: male, 1: female) 0.870 [0.826, 0.917] p < 0.0001
Morbidity (Charlson-Index) 0.998 [0.920, 1.079] n. s.
Health insurance (0: statutory, 1: private) 1.385 [1.240, 1.546] p < 0.0001
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summary of recent studies, which recognised the benefit
of the decreased risk of hypoglycaemia, but also
highlighted potentially disadvantageous long-term effects.
Of particular concern were cases of acute and chronic
pancreatitis as well as malignancies in the pancreas and
thyroid. Other literature comes to similar conclusions, but
these were results of rodent studies [17, 18]. Nevertheless,
in the recently published 2014 meta-analysis from Li et al.
[19] and an assessment co-published by the Food and
Drug Administration und the European Medicine Agency
no causal relationships could be proven between pancrea-
titis and incretin mimetics [20]. A similar conclusion has
been drawn by Nauck et al. [21], who correctly point out
that owing to the modest amount of data available, it is
not possible to completely exclude possible risk.
The European Medicines Agency (EMA) is currently
examining new data on the DPP-4-inhibitor “Saxagliptin”
in terms of mortality since the US-American FDA (Food
and Drug Administration) observed an association be-
tween the intake of Saxagliptin and heightened mortality
in the context of the “SAVOR” study [22].
Recently the FDA warned that DPP-4 inhibitors for
type 2 diabetes may cause severe joint pain [23]. On the
other hand, some studies indicate that cardiovascular
side effects with the DPP-4 inhibitors are less frequent
in comparison to other antihyperglycaemic agents, al-
though it cannot be taken as far as to claim they provide
a protective cardiovascular effect [24–26]. And finally,
new results of the TECOS study demonstrate that the
DDP-4 inhibitor agent “Sitagliptin” reduced the risk of
initiating an additional antihyperglycemic agent during
the study by 28 %. “Sitagliptin” was comparable to other
antihyperglycemic agents regarding the incidence of se-
vere hypoglycemia and the use of this agent had a neu-
tral effect on all cardiovascular outcomes [27, 28].
When FPs are making prescribing decisions for pa-
tients with DM2, aside from taking into account thera-
peutic considerations and advantages of the incretin
mimetics, it needs to be also taken into account that po-
tential long-term risks are as yet unclear. As a classic
lesson, there is the “Glitazones” class of diabetic medica-
tions that in some cases have been withdrawn com-
pletely from the market and in other cases are no longer
recommended due to concerns of increased incidence of
coronary heart disease and myocardial infarction or pos-
sible links to bladder cancer associated with their use
[29, 30]. Currently there is still disagreement between
different expert associations regarding the potential thera-
peutical advantage of the GLP-1 and DDP-4 agents and the
potential risks and side effects of such a therapy [31, 32].
Critical reflection and reference to clinical guidelines
and current literature belongs to good medical practice
when making prescribing decisions and this is equally
relevant for prescription of DPP-4-inhibitors and GLP-1-
agonists, the case under discussion in this paper. It cer-
tainly has to be recognised that with more or less free pre-
scribing in Germany for privately insured patients of new
classes of diabetic drugs such as the incretin mimetics,
these patients have a potential therapeutic advantage over
patients with statutory health insurance due to easier ac-
cess. However, it should be emphasized that in all cases,
good medical practice for prescription decisions related to
DPP-4-inhibitors and GLP-1-agonists should be based on
potential therapeutic advantages and potential disadvan-
tages/risks of the pharmacotherapeutic agents and not
eligibility for reimbursement according to private or statu-
tory health insurance.
The strength of this study include the ability to com-
pare data from patients with either private or statutory
health insurance receiving primary health care services
from the same FP, due to information being continu-
ously collated in a health services research Register from
the family practices collaborating in the CONTENT re-
search network. In contrast to other known German reg-
isters such as DiaRegis [33] or SIRTA [34], our Register
was not explicitly established to investigate research
questions related to DM2. Data from this Register pro-
vides a comprehensive overview of multiple health issues
and their treatments. Currently, the Register has col-
lected morbidity and health services data from a total of
3M Doctor-Patient contacts. The Research Network
CONTENT has much future potential in terms of syner-
gistic effects, in cooperation with other existing registers,
to address research needs and produce evidence with a
focus on primary care health services by FPs for patients
with DM2.
Limitations related to this study include the use of
routine data collected from family practices collaborat-
ing in the CONTENT research network. Data on pre-
scriptions made by specialists (particularly Internal
Medicine) were not available. In addition, other factors
taken into account in therapeutic decision-making be-
side the socio-demographic data (e.g. occupation, leisure
activities, driving) were not available in the register, and
could be relevant. Moreover, is has to be taken into ac-
count that the data was derived from voluntarily partici-
pating FPs within a regional German cluster (mainly
Baden-Württemberg and Hesse, 2 of 16 federal states of
Germany). These factors need to be taken into consider-
ation in terms of the representativeness of the results.
Conclusions
In this sample population of German patients with
DM2, we observed statistically significant differences in
prescription patterns according to the patient’s health in-
surance status for the incretin mimetics. This is clearly
due to differences in the eligibility for reimbursement ac-
cording to patients’ health insurance status. Of concern, is
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the fact that whether incretin mimetics pose specific long
term risks for particular patients is yet to be determined.
In conclusion, whether a patient has private or statutory
health insurance should not determine pharmacothera-
peutic advantages or risks for patient groups with a par-
ticular health problem. This needs to be taken into
account by key stakeholders and decision-makers in the
development of new strategies and measures in health
care service provision.
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